Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease.

被引：0
|
作者：
Rezvani, K
Lalancette, M
Szydlo, R
Mackinnon, S
Blaise, D
Slavin, S
Alessandrino, EP
Michallet, M
Niederwieser, N
Apperley, J
Frassoni, F
机构：
[1] Hammersmith Hosp, London, England
[2] UCL, London, England
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Hadassah Univ, Jerusalem, Israel
[5] Policlin San Matteo, I-27100 Pavia, Italy
[6] Hop Edouard Herriot, Lyon, France
[7] Univ Leipzig, D-7010 Leipzig, Germany
[8] Osped San Martino Genova, Genoa, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2061
引用
收藏
页码：479A / 479A
页数：1
相关论文
共 50 条
  • [21] Persistence of Red Blood Cell Alloantibodies after Non-myeloablative Stem Cell Transplant for Sickle Cell Disease
    Lee, S. Campbell
    James, J.
    Gvozdjan, K.
    Rondelli, D.
    Gordeuk, V. R.
    Saraf, S.
    TRANSFUSION, 2016, 56 : 134A - 134A
  • [22] Non-myeloablative allogeneic stem cell transplantation is feasible in multiple myeloma patients with end-stage renal disease.
    Steel, E
    Gadisseur, APA
    Van de Velde, ALR
    Schroyens, WA
    Zachee, P
    Berneman, ZN
    BLOOD, 2003, 102 (11) : 430B - 431B
  • [23] Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients
    Narreddy, S.
    Mellon-Reppen, S.
    Abidi, M. H.
    Klein, J. L.
    Peres, E.
    Heilbrun, L. K.
    Smith, D.
    Alangaden, G.
    Chandrasekar, P. H.
    TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (01) : 3 - 10
  • [24] Efficacy of performing a second non-myeloablative allogenic stem cell transplant.
    Byrne, BJ
    Antin, JH
    Alyea, EP
    Choa, NJ
    Rizzieri, DA
    BLOOD, 2005, 106 (11) : 1020A - 1020A
  • [25] Non-myeloablative conditioning regimen for allogeneic stem cell transplantation in patients with advanced hematological malignancies
    Malesevic, M
    Stamatovic, D
    Tukic, L
    Marjanovic, S
    Balint, B
    Tarabar, O
    Todoric, B
    Ristic, L
    Milicevic, S
    BONE MARROW TRANSPLANTATION, 2001, 27 : S294 - S295
  • [26] Successful treatment of primary granulocytic sarcoma by non-myeloablative stem cell transplant
    Tan, D
    Wong, GC
    Koh, LP
    Hwang, W
    Loh, Y
    Linn, YC
    Goh, YT
    LEUKEMIA & LYMPHOMA, 2006, 47 (01) : 159 - 162
  • [27] Non-myeloablative stem cell transplant using 2-chlorodeoxyadenosine (2-CdA) in a patient with myelodysplastic syndrome (MDS)
    Saito, T
    Seo, S
    Tanosaki, R
    Takaue, Y
    Mineishi, S
    EXPERIMENTAL ONCOLOGY, 2000, 22 (1-2): : 88 - 90
  • [28] Chronic kidney disease after non-myeloablative stem cell transplantation
    Kersting, S.
    Verdonck, L. F.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S81 - S81
  • [29] Risk factors associated with the development of moderate to severe chronic graft-versus-host disease after non-myeloablative conditioning allogeneic stem cell transplantation in patients with AML or MDS
    Laurence M. C. Kok
    Laura Bungener
    Geertruida H. de Bock
    Anouschka Biswana
    Geertiena van der Wal
    Gustaaf W. van Imhoff
    Mar Bellido
    Human Cell, 2020, 33 : 243 - 251
  • [30] Risk factors associated with the development of moderate to severe chronic graft-versus-host disease after non-myeloablative conditioning allogeneic stem cell transplantation in patients with AML or MDS
    Kok, Laurence M. C.
    Bungener, Laura
    De Bock, Geertruida H.
    Biswana, Anouschka
    Van der Wal, Geertiena
    Van Imhoff, Gustaaf W.
    Bellido, Mar
    HUMAN CELL, 2020, 33 (01) : 243 - 251
12345